Central Nervous System Lymphoma

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free lymphoma classification, results showed.

A literature review presented at the ASCO2020 Virtual Scientific Program showed the efficacy of high-dose chemotherapy in conjunction with allogeneic hematopoietic stem cell transplant in treating central nervous system lymphoma.

Phase 1, interventional pilot trial to research the safety of tisagenlecleucel (Kymriah, Novartis) in participants with primary CNS lymphoma.

Cytoreductive surgery may be an effective treatment option for specific subgroups of patients with primary central nervous system lymphoma, according to results of a systematic review.